Collect the treatment record
Bring the diagnosis, full DXA reports, prior bone medicines, last Prolia date, outside order if one exists, recent laboratory results, kidney history, medicines, supplements, and dental plans.
The visit begins with the clinical question and the records that can change the next step.
The current Prolia label directs administration by a healthcare provider as a subcutaneous injection every six months.
Prolia has a boxed warning for severe hypocalcemia in patients with advanced chronic kidney disease, especially when CKD-mineral and bone disorder is present.
The clinician reviews oral health and dental plans, corrects pre-existing hypocalcemia, and gives individualized calcium and vitamin D instructions.
Stopping, skipping, or delaying Prolia can increase vertebral-fracture risk. A clinician should plan any transition to another osteoporosis treatment.
Bring the diagnosis, full DXA reports, prior bone medicines, last Prolia date, outside order if one exists, recent laboratory results, kidney history, medicines, supplements, and dental plans.
The clinician confirms whether the current FDA-approved indication fits and reviews calcium, kidney disease, pregnancy possibility, dental risk, prior reactions, infection history, and continuity needs.
The care team confirms who prescribes, how the medication is acquired, which clinic can receive and administer it, and when the dose can be scheduled. Availability is not inferred from the general clinic list.
A trained healthcare professional administers the injection after required records and safety checks are complete and the medication has reached the confirmed clinic.
Before leaving the care pathway, record the next target date, required monitoring, responsible prescriber, and what to do if coverage, travel, dental work, or health changes may delay treatment.
Prolia is denosumab, a prescription medicine with several FDA-approved bone-loss indications. The indication, fracture risk, prior therapies, and alternatives need clinician review before the first dose or when transferring care.
The current label includes a boxed warning for severe hypocalcemia in advanced chronic kidney disease. Patients with advanced CKD may need evaluation for chronic kidney disease-mineral and bone disorder and care from a clinician with relevant expertise. A generic injection appointment cannot replace that work.
The plan after a dose matters because the medication is given on a six-month schedule and stopping or delaying it without another treatment plan can raise vertebral-fracture risk. Transfer records should include the exact last-dose date and the clinician responsible for future treatment decisions.
Do not stop, skip, or delay Prolia without speaking with the prescribing clinician. Seek prompt medical attention for symptoms that may reflect severe low calcium, a serious allergic reaction, or another urgent problem. Patients with advanced kidney disease need specialist-level risk review under the current boxed warning.
Book a Prolia evaluation to start the review. The appointment does not promise that Prolia is stocked, accepted from an outside prescriber, covered, or administered at every Nao Medical clinic.
Clinic confirmation
The care team confirms the visit type and an eligible clinic before any product, procedure, or treatment-specific appointment.
Visit preparation
Complete reports and exact prior-dose dates make it easier to review risk, safety, continuity, and the responsible prescriber.
Choose the related care that matches the question you want the clinician to address.
Review fracture risk, outside DXA results, prior medicines, labs, and treatment or referral options first.
Coordinate ongoing conditions, preventive care, records, and referrals through primary care.
Keep menopause symptom management distinct while connecting relevant bone-health questions.
Sources from DailyMed, FDA, and USPSTF were checked on August 1, 2026.
National Library of Medicine DailyMed
Indications, six-month administration, contraindications, laboratory review, dental considerations, and continuity warnings.
Read the official sourceU.S. Food and Drug Administration
Advanced kidney disease risk, calcium monitoring, and the warning against stopping or delaying Prolia without clinical guidance.
Read the official sourceU.S. Preventive Services Task Force
Current screening recommendation for women 65 and older and younger postmenopausal women at increased risk.
Read the official sourceProlia is not a same-day stock service. Do not ship medication or travel to a clinic until the care team confirms the prescriber, product, site, records, and timing.
Medical content checked against the sources above on August 1, 2026.
General information only. This page is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 1, 2026 from the sources cited on this page. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.